Choline Quantification in Breast Cancer by MRS

This study has been withdrawn prior to enrollment.
(We chose to use an exsisting NMR pulse sequence already established and available at the hospital.)
Sponsor:
Collaborator:
The Norwegian Women´s Public Health Association
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00201487
First received: September 16, 2005
Last updated: October 30, 2013
Last verified: October 2013

September 16, 2005
October 30, 2013
November 2007
November 2007   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00201487 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Choline Quantification in Breast Cancer by MRS
Choline Quantification in Breast Cancer by MRS

Choline has been found in increased concentration in breast cancer patients. Hypothesis: The choline signal as observed by MRS is sensitive to treatment, and a positive response to treatment will give a reduction in choline concentration.

The purpose of this study is to establish methods for quantification of choline in breast cancer by MRS

  1. Establishment of new MRS sequence for choline quantification of choline. This sequence is choline-selective, and signals from water and lipids are suppressed simultaneously.
  2. Compare to different methods for choline quantification. The first method is quantification through an external phantom standard, containing a known concentration of choline. The other method is based on the utilisation of internal water signal as a reference.

Both calculations can be performed from the same MR exam. Ten patients will be included in the study.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

breast cancer

Breast Neoplasms
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
November 2007
November 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • breast cancer

Exclusion Criteria:

-

Female
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00201487
11870
No
Norwegian University of Science and Technology
Norwegian University of Science and Technology
The Norwegian Women´s Public Health Association
Principal Investigator: Tone Bathen, PhD NTNU, Faculty of medicine,
Norwegian University of Science and Technology
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP